Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2- Early Breast Cancer.

ABSTRACT:

Background

The prognostic or predictive value of commonly used multigene assays in young patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer is unclear. In this study, we assessed the prognostic value of the GenesWell BCT assay according to age group.

Methods

We identified patients with pN0-1, HR+/HER2- breast cancer in a prospective cohort of women who underwent surgery between 2005 and 2017. The GenesWell BCT assay was performed on tissue samples from selected patients. Distant metastasis-free survival (DMFS) and disease-free survival (DFS) were compared between the risk groups assigned by the BCT score.

Results

A total of 712 patients were eligible for analysis. The median follow-up time was 7

SUBMITTER: Kwon MJ 

PROVIDER: S-EPMC7942224 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature